Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
ID: 344598Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344598

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-026.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled “Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)” aimed at supporting time-sensitive ancillary studies that leverage resources from active clinical projects related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Eligible applicants include a diverse range of institutions such as higher education entities, nonprofits, for-profit organizations, and government agencies, with a funding limit of $400,000 over a two-year period. This initiative emphasizes innovative research that enhances the understanding of diseases while ensuring that ancillary studies do not disrupt parent projects, encouraging interdisciplinary collaboration. Interested applicants should note that the application deadline is December 5, 2025, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-026.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-026.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), issued a funding opportunity titled “Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed).” The announcement aims to support time-sensitive ancillary studies related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), leveraging resources from active clinical projects. Eligible applicants include various higher education institutions, nonprofits, for-profit organizations, and government entities, with direct costs limited to $400,000 over two years. Key points of the application include a focus on innovative research that enhances the understanding of diseases, emphasizing the importance of well-characterized patient cohorts. Ancillary studies must not disrupt parent projects and are encouraged to collaborate across disciplines. The review process will be accelerated for applications showing clear time sensitivity related to the parent project. Notably, the FOA prohibits clinical trials and requires adherence to NIH policies. Critical submission requirements include timely registration, adherence to application instructions, and obtaining approval from parent study committees. The objectives are to promote groundbreaking research that identifies new targets for disease diagnosis, treatment, and prevention while efficiently using existing resources.
    Similar Opportunities
    Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Ancillary Studies to Ongoing Clinical Projects" funding opportunity through the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support time-sensitive ancillary studies related to active interventional clinical trials or observational studies, enhancing scientific understanding in alignment with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Eligible applicants include a diverse range of institutions, with a budget cap of $400,000 over two years, and projects must demonstrate time sensitivity and integration with existing studies. Interested parties can find more information and application guidelines at the NIH website, with a submission deadline of December 5, 2025.
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Ancillary Studies to Ongoing Clinical Projects funding opportunity (PAR-23-025), aimed at supporting time-sensitive ancillary studies that enhance scientific knowledge related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). These studies must utilize existing cohorts, data, and biological samples to explore novel research questions that extend beyond the scope of the parent projects, with an emphasis on collaboration between junior and senior researchers. Grants may provide up to $300,000 per year for a duration of up to four years, with applications accepted until December 6, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Ancillary Studies to Ongoing Clinical Projects" grant (FON: PAR-24-289), aimed at supporting time-sensitive ancillary studies that leverage existing resources from active clinical projects related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This funding opportunity encourages innovative research that enhances the scientific content of parent projects, with eligible studies potentially including interventional trials or observational studies that utilize well-characterized cohorts, data, and biological samples. The total budget for direct costs is capped at $300,000 per year, with projects lasting a maximum of four years, and applications must be submitted electronically by September 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases under the R01 Research Project Grant program. This initiative aims to support observational studies that gather critical data to inform future clinical research, focusing on understanding disease symptoms, progression, participant recruitment strategies, and potential biomarkers. The funding opportunity is significant for enhancing research outcomes in health fields related to these diseases, with applicants eligible to request up to $475,000 over four years. Key deadlines include an application submission start date of February 4, 2025, and a final expiration date of November 3, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding opportunities through the "Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases" program, specifically under the R61 Clinical Trial mechanism. This initiative aims to support short-term exploratory clinical trials that investigate treatments for rheumatic, musculoskeletal, and skin conditions, with a focus on diverse therapeutic approaches. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and state and local governments, with a maximum budget of $600,000 for a three-year project, not exceeding $300,000 in any single year. Applications must be submitted electronically via Grants.gov, with key deadlines starting from February 4, 2024, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) to support innovative research projects in the early stages that can lead to significant advancements in biomedical, behavioral, and clinical research. This funding opportunity requires applicants to propose at least one clinical trial and is aimed at addressing critical gaps in knowledge within the scientific missions of participating NIH Institutes and Centers. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and foreign entities, with a total project period limited to two years and a budget of up to $275,000. The application period opens on January 16, 2025, and closes on January 8, 2028; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is offering a funding opportunity for the implementation of interventional clinical trials via the Clinical Trial Implementation Cooperative Agreement (UG3/UH3). This initiative aims to support investigation-driven projects for both single and multi-site trials across all phases, emphasizing the importance of preliminary planning and the completion of necessary approvals before trial execution. The funding opportunity reflects NIAMS' commitment to advancing research in arthritis and musculoskeletal diseases, with grants of up to $250,000 available for the UG3 phase and no specific limit for UH3 project budgets, designed for up to six years of support. Interested applicants can find more information and application details at the provided link, with the application deadline set for March 4, 2027.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) to support innovative early-stage research projects that may lead to significant advancements in biomedical, behavioral, or clinical fields. This grant is designed to encourage high-risk, high-reward research, providing funding for projects that are distinct from traditional R01 grants, with a maximum budget of $275,000 over a two-year period, and no more than $200,000 in any single year. Eligible applicants include a wide range of organizations such as educational institutions, nonprofit organizations, and tribal governments, with applications undergoing a rigorous peer review process to assess their innovation and feasibility. Interested parties should note that the application submission period begins on January 16, 2025, with the opportunity closing on January 7, 2028; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.